Pharmaceuticals
Our global Pharmaceuticals portfolio includes more than 45 key marketed products, many of which are leaders in their respective therapeutic areas. We have received 17 new pharmaceutical product approvals in the US since 2000, the most of any pharmaceutical company.
Key pharmaceutical products marketed by Novartis are listed below by therapeutic area.
Click on the product link where available to display complete product information. Please note that some product links are intended for US residents only.
A-Z
A C D E F G L M N P R S T V X Z
Sandostatin SC/Sandostatin LAR (octreotide acetate)
Acromegaly, carcinoid tumors and other types of gastrointestinal neuroendocrine and pancreatic tumors
Visit www.sandostatin.com
Visit www.us.sandostatin.com (US residents only)
Sebivo/Tyzeka (telbivudine)
Chronic hepatitis B
Visit www.tyzeka.com (US residents only)
Simulect
Prevention of acute organ rejection
Stalevo (carbidopa/levodopa/entacapone)
Parkinson's disease
Visit www.stalevo.com (US residents only)
Starlix
Type 2 diabetes
Visit www.starlix.com (US residents only)
Pharmaceuticals business at Novartis
Novartis discovers and develops innovative medicines with improved efficacy and fewer side-effects.
Latest news
Patient groups
Our commitment to high-quality healthcare has led to an enduring and trusted partnership between Novartis and various patient groups.